Why carry out this study?

While the broad and sustained efficacy of apremilast for the treatment of psoriasis has been demonstrated in randomized and real-world observational studies, its use in clinical practice varies according to country-specific reimbursement criteria

A better understanding of the clinical value of apremilast in different countries and patient populations could potentially improve the care and outcomes of psoriasis patients

The APPRECIATE study assessed the clinical value of apremilast for the treatment of psoriasis across multiple European countries from the perspectives of the patient and their treating physician

What was learned from the study?

Compared with the overall study population, patients from Central and Eastern Europe had more severe psoriasis, a higher rate of prior systemic therapy, and highly impaired quality of life

Despite these differences, patients from Central and Eastern Europe experienced substantial improvements in disease signs and symptoms and reported apremilast met or exceeded their expectations, demonstrating the clinical value of apremilast in this region